API event sites ...


API's topic library ...
The topic sites in our library offer gateways to information on body condition scoring, beef cow efficiency, country-of-origin labeling, targeting the Certified Angus Beef® brand and more.


Sign up for ...



Angus Productions Inc.
Copyright © 2011
Angus Productions Inc.

Express® Vaccine Expands Reproductive Protection

Express® FP 5-LV5, a new product from Boehringer Ingelheim Vetmedica Inc. features expanded reproductive protection for beef or dairy cattle.

SAINT JOSEPH, Mo. (Jan. 21, 2011) —- Boehringer Ingelheim Vetmedica Inc. introduces a vaccine that steps beyond conventional reproductive protection. Express FP 5-VL5 currently provides one of the most complete modified-live virus (MLV)/bacterin vaccine combinations on the market, and now it offers protection against Leptospira hardjo-bovis.


Lepto hardjo-bovis is associated with early embryonic deaths, poor conception rates and weak calves, as well as other reproductive losses in cattle. Express FP 5-VL5 offers five-way viral protection and protection against Lepto hardjo-bovis in just one syringe.


Lepto hardjo-bovis (Leptospira borgpetersenii serovar hardjo type hardjo-bovis) is the only hardjo that is isolated in the United States. All cattle herds are at risk for infection from it. In a recent study, challenged heifers vaccinated with Express FP 5-VL5 were 100% protected against urinary shedding of Lepto hardjo-bovis, while urine culture tests for all heifers in the control group were positive.*


“As demonstrated by new label claims and the guarantee Boehringer Ingelheim Vetmedica puts behind this product, the introduction of Express FP 5-VL5 offers the cattle industry an effective vaccine for reproductive and respiratory protection in the cow herd,” says Joe Campbell, Boehringer Ingelheim Vetmedica, Inc. professional services veterinarian.


This new product also includes antigens for bovine respiratory syncytial virus (BRSV) and parainfluenza-3 (PI-3), as well as new label claims for prevention of urinary shedding of Lepto hardjo-bovis and aids in the prevention of key respiratory viruses. The expanded respiratory label adds to the reproductive protection in beef and dairy cattle for which Express FP products have long been known.


The Express FP line of vaccines for breeding animals offers producers the original written guarantee that no calf persistently infected with BVD will be born from a properly vaccinated cow. It is reproductive and respiratory protection that producers can count on every time.


“Express FP was the first modified-live viral vaccine to offer a written guarantee that calves born to a dam properly vaccinated with Express FP would be free of BVD persistent infection,” Campbell says. “This vaccine was created with your herd’s reproductive health in mind, protecting your animals against major reproductive diseases. The efficacy of Express FP has always been our top priority, and we will continue to offer that guarantee on our product.”


Read and follow all product label directions. For more information on Express FP, contact your veterinarian or Boehringer Ingelheim Vetmedica Inc. representative.


For more information, please visit: www.bi-vetmedica.com.



*Protection for L. borgpetersenii serovar hardjo using Express FP. BIVI TB10-138.


Boehringer Ingelheim Vetmedica Inc. (Saint Joseph, Mo.) is a subsidiary of Boehringer Ingelheim Corp., based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and approximately 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2009, Boehringer Ingelheim posted net sales of US $17.7 billion (12.7 billion euro) while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.



Editor’s Note: The above article is adapted from a news release provided by the American Angus Association. For other Association news, visit www.angus.org.


www.4cattlemen.com is an event coverage site provided by the editorial team at Angus Productions Inc. (API), publisher of the Angus Journal, the Angus Beef Bulletin, the Angus Beef Bulletin EXTRA and the Angus e-List. For questions about this site, to submit an article for our consideration, or to report a broken link, contact the editor at 816-383-5200; 3201 Frederick Ave., Saint Joseph, MO 64506.


API claims copyright to this web site as presented. We welcome educational venues and cattlemen to link to this site as a service to their audience.